Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2026)

Catalyst Pharmaceuticals (CPRX) has 4 years of Finished Goods data on file, last reported at $15.3 million in Q1 2026.

• Quarterly Finished Goods rose 88.21% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (up 88.21% YoY) and the FY2025 annual result came in at $16.2 million, up 68.7% from the prior year.
• Finished Goods retreated to $15.3 million in Q1 2026, from $16.2 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $16.2 million in Q4 2025 to a low of $8.1 million in Q1 2025.
• A 4-year average of $10.6 million and a median of $9.2 million in 2024 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2025 — Finished Goods fell 3.29% — and 2026, when it jumped 88.21%.
• Tracing CPRX's Finished Goods over 4 years: stood at $9.2 million in 2023, then grew by 4.55% to $9.6 million in 2024, then soared by 68.7% to $16.2 million in 2025, then slipped by 5.43% to $15.3 million in 2026.
• The last three Finished Goods figures came in at $15.3 million (Q1 2026), $16.2 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.